Commercial & Pipeline Insight: Vaccines for Adults & the Elderly
Price:
$15 200.00
Full Title: Commercial and Pipeline Insight: Vaccines for Adults and the Elderly - New blockbuster opportunities ahead
Introduction
Vaccines have re-emerged as successful revenue generators for Big Pharma, with adults and the elderly now increasingly coming into focus as the next big opportunity in this sector. An aging population, rising disease awareness and new technologies to overcome the scientific hurdles linked to the weakened immune response in the elderly are all contributing factors.
Scope
Assessment of pneumococcal and zoster disease incidence, in-depth analysis of existing vaccines and key pipeline compounds
Review of current and expected future immunization guidelines as well as existing and forecast immunization rates
10-year sales forecast on a population basis for Zostavax, Prevnar 13 and Pneumovax-23
Overview of current booster vaccine recommendations and commercial landscape with analysis of future market drivers
Highlights
Following the great success of Wyeth’s heptavalent pneumococcal vaccine Prevnar in the infant sector, Datamonitor believes that Prevnar 13 could achieve blockbuster status in adults and elderly alone, if a superior efficacy compared to Pneumovax 23 is confirmed in ongoing clinical trials.Merck & Co’s Zostavax is the only available vaccine for the prevention of shingles and will continue to enjoy a monopoly in this promising market due to a lack of pipeline competitors. Datamonitor predicts peak sales between $1.5 and $2 billion.Sanofi Pasteur and GSK are the leading players in the booster vaccines market. Overall, Datamonitor predicts significant growth potential in this sector, based on both geographic expansion of existing booster indications as well as the potential introduction of additional booster vaccinations for new indications.
Reasons to Purchase
Size the available market opportunities and identify the unmet medical needs when immunizing an elderly patient population
Gain insight into key opinion leaders’ thinking on vaccines for the elderly
Understand and identify the key challenges to achieving a better penetration of the next big opportunity in the vaccine area
